Development of an in-house bone marrow collection kit: The Catalan bone marrow transplantation group experience.
bone
collection
commercial
in-house
kit
marrow
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
revised:
28
05
2023
received:
30
12
2022
accepted:
07
06
2023
medline:
15
9
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
ppublish
Résumé
Bone marrow (BM) harvesting is one of the essential sources of stem cells for haematopoietic stem cell transplantation. In 2019, commercial BM collection kits became unavailable in Europe. Consequently, we created an in-house BM collection kit as an alternative. We compared two groups of BM collections. The first collections were taken using an in-house kit from June 2022 through February 2023 and the second with a commercial kit from February 2021 through May 2022. These all took place at seven collection centres (CC). We analysed the harvest quality (cell blood count, CD34+ cells, viability, potency and sterility), the incidents occurring with each kit and the time to neutrophil and platelet engraftment in recipients. A total of 23 donors underwent BM harvesting with the in-house kit and 23 with the commercial one. Both cohorts were comparable regarding donor characteristics, CC and time to procedure. No statistical differences were found in harvest quality between the in-house and commercial kits. A new transfusion set was required in three BM harvests (13%) with the in-house kit because of filter clogging. The median time to neutrophil and platelet engraftment was 21 days for both cohorts and 29 days (in-house) and 33 days (commercial), p = 0.284, respectively. The in-house BM collection kit offers a real approach to solve the diminished supply of commercial kits. A higher risk of filter clogging was observed compared with commercial kits due to the lack of 850 and 500 μm filters.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Bone marrow (BM) harvesting is one of the essential sources of stem cells for haematopoietic stem cell transplantation. In 2019, commercial BM collection kits became unavailable in Europe. Consequently, we created an in-house BM collection kit as an alternative.
MATERIALS AND METHODS
METHODS
We compared two groups of BM collections. The first collections were taken using an in-house kit from June 2022 through February 2023 and the second with a commercial kit from February 2021 through May 2022. These all took place at seven collection centres (CC). We analysed the harvest quality (cell blood count, CD34+ cells, viability, potency and sterility), the incidents occurring with each kit and the time to neutrophil and platelet engraftment in recipients.
RESULTS
RESULTS
A total of 23 donors underwent BM harvesting with the in-house kit and 23 with the commercial one. Both cohorts were comparable regarding donor characteristics, CC and time to procedure. No statistical differences were found in harvest quality between the in-house and commercial kits. A new transfusion set was required in three BM harvests (13%) with the in-house kit because of filter clogging. The median time to neutrophil and platelet engraftment was 21 days for both cohorts and 29 days (in-house) and 33 days (commercial), p = 0.284, respectively.
CONCLUSION
CONCLUSIONS
The in-house BM collection kit offers a real approach to solve the diminished supply of commercial kits. A higher risk of filter clogging was observed compared with commercial kits due to the lack of 850 and 500 μm filters.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
783-789Informations de copyright
© 2023 International Society of Blood Transfusion.
Références
Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022;57:1217-1239.
EBMT. Transplant activity survey 2022 summary. [cited 2022 Dec 17]. Available from: https://www.ebmt.org/registry/transplant-activity-survey
European Union. Regulation EU 2017/745 on medical devices (medical device regulation, MDR). [cited 2022 Dec 17]. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R0745
Lanza F, Saccardi R, Seghatchian J. New horizons on stem cell cryopreservation through the artificial eyes of CD34 using modern flow cytometry tools. Transfus Apher Sci. 2020;59:102785.
Thomas ED, Storb R. Technique for human marrow grafting. Blood. 1970;36:507-515.
Rovira R, Carreras E. Obtención de PH de médula ósea. In: Rovira R, Carreras E, Valcarcel D, editors. Manual de Trasplante hematopoyético y terapia celular. 6th ed. Barcelona, Spain: Mediúscula; 2022. p. 78-82.
EBMT. Cellular therapy forms manual. [cited 2022 Dec 17]. Available from: https://www.ebmt.org/sites/default/files/2022-06/Final%20Registry%2063_Cellular%20Therapy%20Forms%20Manual%20%28Castor%29_v1.0%20with%20footer.pdf
Maziarz RT, Diaz A, Miklos DB, Shah NN. Perspective: an international fludarabine shortage: supply chain issues impacting transplantation and immune effector cell therapy delivery. Transplant Cell Ther. 2022;28:723-726.
Pruszczyk K, Skwierawska K, Król M, Moskowicz A, Jabłoński D, Torosian T, et al. Bone marrow harvest from unrelated donors-up-to-date methodology. Eur J Haematol. 2017;99:357-365.
Spitzer TR. Bone marrow collection. In: Areman EM, Loper K, editors. Cellular therapy: principles, methods, and regulations. 2nd ed. Bethesda, MD: AABB; 2016. p. 294-306.
Prokopishyn NL, Logan BR, Kiefer DM, Sees JA, Chitphakdithai P, Ahmed IA, et al. The concentration of total nucleated cells in harvested bone marrow for transplantation has decreased over time. Biol Blood Marrow Transplant. 2019;25:1325-1330.
Klein MA, Kadidlo D, McCullough J, McKenna DH, Burns LJ. Microbial contamination of hematopoietic stem cell products: incidence and clinical sequelae. Biol Blood Marrow Transplant. 2006;12:1142-1149.
Patah PA, Parmar S, McMannis J, Sadehi T, Karandish S, Rondon G, et al. Microbial contamination of hematopoietic progenitor cell products: clinical outcome. Bone Marrow Transplant. 2007;40:365-368.
Vanneaux V, Foïs E, Robin M, Rea D, de Latour RP, Biscay N, et al. Microbial contamination of BM products before and after processing: a report of incidence and immediate adverse events in 257 grafts. Cytotherapy. 2007;9:508-513.
Fresenius Kabi. Bone marrow collection kit. [cited 2022 Dec 17]. Available from: https://www.fresenius-kabi.com/kr/documents/Bone_Marrow_Collection_Kit_-_Product_Folder.pdf